Veracyte is trading at $45.97, up +4.03%, likely reflecting a broader market rebound after weaker-than-expected September payrolls eased rate-hike concerns. - Reuters reported gains in U.S. stock futures following the jobs report. - No clear company-specific catalyst was identified. Veracyte’s recently reported prostate-test findings predate October 2 and do not establish a direct cause for the day’s gain.